



PATENT
Attorney D. No.: 082375-000000US
Client Reference No.: M3-104PCT-US

#6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Suzuki et al.

Application No.: 10/049,336

Filed: February 4, 2002

For: METHOD FOR MEASURING
KINASE ACTIVITY OF CYCLIN/CDK
COMPLEX

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Assistant Commissioner for Patents
Washington, D.C. 20231


Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. Also enclosed is a copy of the Preliminary Examination report corresponding to the PCT application. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Joe Liebeschuetz
Reg. No. 37,505

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 650-326-2400
Fax: 650-326-2422
JOL:crf



Substitute for form 1449A-PTO

C mplete if Kn wn

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---


Application Number	10/049,336
Filing Date	February 4, 2002
First Named Inventor	Suzuki
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	082375-000000US

[illegible][illegible]

Date Considered

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**



Substitute for form 1449B/PTO-101
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/049,336
Filing Date	February 4, 2002
First Named Inventor	Suzuki
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	082375-000000US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AC	AZZI et al., "Interaction between the cell-cycle-control proteins p34 ^{cdc2} p9 ^{CKShs2} Evidence for two cooperative binding domains in p9 ^{CKShs2} ," <u>Eur. J. Biochem.</u> , 203:353-360 (1992).	
	AD	KITAGAWA et al., "The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2," <u>EMBO J.</u> , 15(24):7060-7069 (1996).	
	AE	MEIJER et al., "Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependant kinases cdc2, cdk2 and cdk5," <u>Eur. J. Biochem.</u> , 243:527-536 (1997).	
	AF	VESELY et al., "Inhibition of cyclin-dependant kinases by purine analogues," <u>Eur. J. Biochem.</u> , 224:771-786 (1994).	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
PA 3233891 v1